Navigation Links
Hepatitis C responds best to combo of ribavirin and interferon, study concludes

A combination of the drugs ribavirin and interferon is more effective in treating hepatitis C than using interferon alone, but it also increases the risk of side effects, according to a new systematic review of recent evidence.

"Adding ribavirin to any type of interferon should be considered the treatment of choice for patients with hepatitis C," conclude Jesper Brok, M.D., and colleagues at Copenhagen University Hospital.

However, the authors caution that only one in four patients treated with the combination therapy actually had a sustained response.

The researchers reviewed 72 randomized trials and 9,991 patients who had chronic hepatitis C for more than six months and were previously untreated, who had relapsed after treatment or who had not responded to other treatment.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Hepatitis C is inflammation of the liver caused by the hepatitis C virus (HCV). It is transmitted primarily by blood-to-blood contact through a variety of means such as sexual contact, intravenous drug use and needle stick accidents. The disease progresses slowly over 10 to 30 years, causing inflammation and severe scarring of the liver. If untreated, it can lead to liver failure, liver cancer and death.

According to the Centers for Disease Control and Prevention, 170 million people worldwide are infected with HCV, and in the United States, alcoholic liver disease and chronic hepatitis C are the leading causes of cirrhosis. An additional estimated 25,000 new cases of HCV occur in the United States each year.

Interferons have been proven effective in treating HCV by enhancing certain cellular activities such their a
'"/>

Source:Center for the Advancement of Health


Page: 1 2 3

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
8. Hepatitis C complicated by morphine withdrawal
9. Hepatitis B accounts for 40 percent of missing Asian women
10. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
11. Hepatitis E takes a piggyback
Post Your Comments:
(Date:7/27/2014)... new in vitro study has revealed that nicotine and ... damage caused by a certain carcinogen in smoke. , ... curing of tobacco leaves and ultimately ends up in ... the lung and liver, where it is activated by ... research in mice has revealed that nicotine can partially ...
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... can evade treatment by acquiring mutations in the genes ... were once thought to be the only way for ... shown that microorganisms can use a temporary silencing of ... the benefits of drug resistance without the commitment. , ... called Mucor circinelloides, it is likely to be employed ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... new mechanism of infection for the most fatal bee ... which can kill entire colonies of bees. Every year, ... beekeepers all over the world. The only control measure ... of infection (pathogenic mechanism) was originally thought to be ...
... 1 Stinger Systems, Inc. (OTC,Bulletin Board: STIY), ... had reached a settlement agreement with the Securities ... settled the matter without admitting or,denying wrongdoing and ... Systems, Inc. also said that no fines or ...
... of physical oceanographers including a researcher from Scripps Institution ... oxygen-poor regions of tropical oceans are expanding as the ... and other marine organisms can live or enter in ... by Lothar Stramma from the Leibniz Institute of Marine ...
Cached Biology News:Bees disease -- 1 step closer to finding a cure 2Oxygen depletion: A new form of ocean habitat loss 2
(Date:7/25/2014)... July 25, 2014 WABC Radio show out ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s ... stem cell therapy in pets. Dr. Harman first visited ... stem cell therapy for pets suffering from osteoarthritis and other ... Veterinary Medicine industry forward. , Young has invited Dr. Harman ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... 2014 -- A novel combination of microscopy and data ... Oak Ridge National Laboratory an unprecedented look at the ... and electrochemical properties. , The research team led ... surface of a perovskite manganite, a complex material that ... to understand surface behavior could benefit researchers who are ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... , SAN MARINO, Calif., Aug. 26 ... drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this ... collegestock.com on August 25 and August 26, and an article published ... Something About Viral Genetics, Inc. (VRAL)," on August 25. , ...
... , KENILWORTH, N.J., Aug. 26 Schering-Plough ... European Medicines Agency (EMEA) has validated (accepted for review) the ... mometasone furoate and formoterol fumarate for the maintenance treatment of ... The company also announced today that the EMEA has validated ...
... , , DURHAM, N.C., Aug. ... that the company will present at investor conferences in New York ... , Kirk Harrington, senior vice president, Warfighter Division and ... Investment Conference in New York on September 9, 2009 at 2:00 ...
Cached Biology Technology:Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 2Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 3Schering-Plough Announces Two European Filings 2Schering-Plough Announces Two European Filings 3Schering-Plough Announces Two European Filings 4Schering-Plough Announces Two European Filings 5Schering-Plough Announces Two European Filings 6Schering-Plough Announces Two European Filings 7Schering-Plough Announces Two European Filings 8Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich 2
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution....
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Biology Products: